Life Biosciences disclosed it dosed the first participant in a gene therapy trial built on partial cellular reprogramming to coax aged cells toward a younger identity. The approach turns on three genes intended to regenerate neurons in the optic nerve for glaucoma, with safety as the primary early objective. The company’s choice of the eye as the first site reflects a field-wide risk calculus: partial reprogramming has shown potential in preclinical models, but there is concern about cell-state tipping that could raise cancer risk. Early human dosing will be watched for adverse signals and proof of biological activity. The development also advances a broader therapeutic thesis—translation of reprogramming beyond experimental biology into controlled disease targeting—with regulators likely to require tight monitoring around cell fate and proliferation markers.